Publications

Detailed Information

Efficacy and Safety of Low-Dose Cyclosporine Relative to Immunomodulatory Drugs Used in Atopic Dermatitis: A Systematic Review and Meta-Analysis

DC Field Value Language
dc.contributor.authorKim, Kyunghoon-
dc.contributor.authorKim, Mina-
dc.contributor.authorRhee, EunHee-
dc.contributor.authorLee, Mi-Hee-
dc.contributor.authorYang, Hyeon-Jong-
dc.contributor.authorPark, Suyeon-
dc.contributor.authorKim, Hwan Soo-
dc.date.accessioned2024-05-13T07:32:27Z-
dc.date.available2024-05-13T07:32:27Z-
dc.date.created2023-04-07-
dc.date.created2023-04-07-
dc.date.issued2023-02-
dc.identifier.citationJournal of Clinical Medicine, Vol.12 No.4, p. 12041390-
dc.identifier.issn2077-0383-
dc.identifier.urihttps://hdl.handle.net/10371/201597-
dc.description.abstractCyclosporine A (CsA) is effective in treating moderate-to-severe atopic dermatitis (AD). This systematic review and meta-analysis aimed to summarize the effectiveness and safety of low-dose (<4 mg/kg) versus high-dose (>= 4 mg/kg) CsA and other systemic immunomodulatory agents in patients with AD. Five randomized controlled trials met the inclusion criteria. The meta-analysis included 159 patients with moderate-to-severe AD who were randomized to receive low-dose CsA, and 165 patients randomized to receive high-dose CsA and other systemic immunomodulatory agents. We found that low-dose CsA was not inferior to high-dose CsA and other systemic immunomodulatory agents in reducing AD symptoms [standard mean difference (SMD) -1.62, 95% confidence interval (CI) -6.47; 3.23]. High-dose CsA and other systemic immunomodulatory agents showed a significantly lower incidence of adverse events [incidence rate ratio (IRR) 0.72, 95% CI 0.56; 0.93], however, after sensitivity analysis, there was no difference between the two groups except for one study (IRR 0.76, 95% CI 0.54; 1.07). Regarding serious adverse events requiring discontinuation of treatment, we observed no significant differences between low-dose CsA and other systemic immunomodulatory agents (IRR 1.83, 95% CI 0.62; 5.41). Our study may justify the use of low-dose CsA rather than high-dose CsA and other systemic immunomodulatory agents in moderate-to-severe AD.-
dc.language영어-
dc.publisherMDPI AG-
dc.titleEfficacy and Safety of Low-Dose Cyclosporine Relative to Immunomodulatory Drugs Used in Atopic Dermatitis: A Systematic Review and Meta-Analysis-
dc.typeArticle-
dc.identifier.doi10.3390/jcm12041390-
dc.citation.journaltitleJournal of Clinical Medicine-
dc.identifier.wosid000944983000001-
dc.identifier.scopusid2-s2.0-85148937130-
dc.citation.number4-
dc.citation.startpage12041390-
dc.citation.volume12-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Kyunghoon-
dc.type.docTypeReview-
dc.description.journalClass1-
dc.subject.keywordPlusLONG-TERM TREATMENT-
dc.subject.keywordPlusECZEMA-
dc.subject.keywordPlusMETHOTREXATE-
dc.subject.keywordPlusADULTS-
dc.subject.keywordPlusGUIDELINES-
dc.subject.keywordPlusEXPERIENCE-
dc.subject.keywordPlusPREGNANCY-
dc.subject.keywordPlusCHILDREN-
dc.subject.keywordAuthoratopic dermatitis-
dc.subject.keywordAuthorcyclosporine A-
dc.subject.keywordAuthorefficacy-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area 식품알레르기, 아토피피부염, 천식

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share